Asthma exacerbations: Predisposing factors and prediction rules

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 3, 2013, Pages 225-236

  Greenberg, Steven ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

asthma exacerbations; biomarkers; epidemiology; outcome measures

Indexed keywords

CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; EOTAXIN 2; IMMUNOGLOBULIN E; NONSTEROID ANTIINFLAMMATORY AGENT; TOBACCO SMOKE;

ASTHMA; ATOPY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; DUST; EMERGENCY WARD; ENVIRONMENTAL EXPOSURE; EOSINOPHIL; ETHNIC DIFFERENCE; FORCED EXPIRATORY VOLUME; GENETIC ASSOCIATION; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MENSTRUATION; MENTAL DISEASE; OCCUPATIONAL EXPOSURE; PARANASAL SINUS DISEASE; PATIENT IDENTIFICATION; PREPUBERTY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT INFECTION; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKE; SOCIAL STATUS; TH2 CELL;

ANIMALS; ASTHMA; BIOLOGICAL MARKERS; BRONCHIAL HYPERREACTIVITY; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; IMMUNITY; PREDICTIVE VALUE OF TESTS; RESPIRATORY TRACT INFECTIONS; RISK FACTORS;

EID: 84876912765     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32836096de     Document Type: Review

References (183)

1. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405-1411. (Pubitemid 27497887)
2. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007; 30:452-456. (Pubitemid 351182067)
3. O'Byrne PM, Pedersen S, Lamm CJ, et al. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009; 179:19-24.
4. Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011; 128:1185-1191.
5. Fuhlbrigge A, Peden D, Apter AJ, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol 2012; 129:S34-S48.
6. US Department of Health and Human Services, National Institute of Health, National Heart, Lung, and Blood Institute. Expert Panel Report 3: guidelines for the diagnosis and management of asthma. NIH Publication Number 08-5846. 2007.
7. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180:59-99.
8. Moorman JE, Akinbami LF, Bailey CM, et al. National Surveillance of Asthma: United States, 2001-2010. National Center for Health Statistics Vital Health Stat 2012; 3.
9. Schatz M, Clark S, Emond JA, et al. Sex differences among children 2-13 years of age presenting at the emergency department with acute asthma. Pediatr Pulmonol 2004; 37:523-529. (Pubitemid 38680119)
10. Skobeloff EM, Spivey WH, St Clair SS, Schoffstall JM. The influence of age and sex on asthma admissions. JAMA 1992; 268:3437-3440. (Pubitemid 23002747)
11. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999; 160:594-599. (Pubitemid 29380678)
12. Borish L, Chipps B, Deniz Y, et al. Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2005; 95:247-253. (Pubitemid 41376794)
13. Leynaert B, Sunyer J, Garcia-Esteban R, et al. Gender differences in prevalence, diagnosis and incidence of allergic and nonallergic asthma: a population-based cohort. Thorax 2012; 67:625-631.
14. Redmond AM, James AW, Nolan SH, Self TH. Premenstrual asthma: emphasis on drug therapy options. J Asthma 2004; 41:687-693. (Pubitemid 39546312)
15. Eisner MD, Katz PP, Yelin EH, et al. Risk factors for hospitalization among adults with asthma: the influence of sociodemographic factors and asthma severity. Respir Res 2001; 2:53-60. (Pubitemid 34187906)
16. Griswold SK, Nordstrom CR, Clark S, et al. Asthma exacerbations in North American adults: who are the 'frequent fliers' in the emergency department? Chest 2005; 127:1579-1586. (Pubitemid 46218782)
17. Apter AJ, Reisine ST, Affleck G, et al. Adherence with twice-daily dosing of inhaled steroids: socioeconomic and health-belief differences. Am J Respir Crit Care Med 1998; 157:1810-1817.
18. Cabana MD, Lara M, Shannon J. Racial and ethnic disparities in the quality of asthma care. Chest 2007; 132:810S-817S. (Pubitemid 350136391)
19. Rumpel JA, Ahmedani BK, Peterson EL, et al. Genetic ancestry and its association with asthma exacerbations among African American subjects with asthma. J Allergy Clin Immunol 2012; 130:1302-1306.
20. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma pheno-types using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315-323.
21. Peters JI, McKinney JM, Smith B, et al. Impact of obesity in asthma: evidence from a large prospective disease management study. Ann Allergy Asthma Immunol 2011; 106:30-35.
22. Holguin F, Bleecker ER, Busse WW, et al. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol 2011; 127:1486-1493.
23. Chilmonczyk BA, Salmun LM, Megathlin KN, et al. Association between exposure to environmental tobacco smoke and exacerbations of asthma in children. N Engl J Med 1993; 328:1665-1669. (Pubitemid 23157348)
24. Eisner MD. Environmental tobacco smoke and adult asthma. Exp Lung Res 2005; 31 (Suppl 1):8-14. (Pubitemid 41361776)
25. Henneberger PK, Mirabelli MC, Kogevinas M, et al. The occupational contribution to severe exacerbation of asthma. Eur Respir J 2010; 36:743-750.
26. Samoli E, Nastos PT, Paliatsos AG, et al. Acute effects of air pollution on pediatric asthma exacerbation: evidence of association and effect modification. Environ Res 2011; 111:418-424.
27. Hyland ME, Whalley B, Halpin DM, et al. Frequency of nonasthma GP visits predicts asthma exacerbations: an observational study in general practice. Prim Care Respir J 2012; 21:405-411.
28. ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26:812-818. (Pubitemid 41632037)
29. Koga T, Oshita Y, Kamimura T, et al. Characterisation of patients with frequent exacerbation of asthma. Respir Med 2006; 100:273-278. (Pubitemid 43078979)
30. Magadle R, Berar-Yanay N, Weiner P. The risk of hospitalization and near-fatal and fatal asthma in relation to the perception of dyspnea. Chest 2002; 121:329-333. (Pubitemid 34132965)
31. Schatz M, Dombrowski MP, Wise R, et al. Asthma morbidity during pregnancy can be predicted by severity classification. J Allergy Clin Immunol 2003; 112:283-288. (Pubitemid 36981367)
32. Louik C, Schatz M, Hernandez-Diaz S, et al. Asthma in pregnancy and its pharmacologic treatment. Ann Allergy Asthma Immunol 2010; 105:110-117.
33. Tantisira KG, Silverman ES, Mariani TJ, et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol 2007; 120:1285-1291. (Pubitemid 350216603)
34. Chupp GL, Lee CG, Jarjour N, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007; 357:2016-2027. (Pubitemid 350106709)
35. Cunningham J, Basu K, Tavendale R, et al. The CHI3L1 rs4950928 polymorphism is associated with asthma-related hospital admissions in children and young adults. Ann Allergy Asthma Immunol 2011; 106:381-386.
36. Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008; 358:1682-1691. (Pubitemid 351549915)
37. Lee CG, Hartl D, Lee GR, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009; 206:1149-1166.
38. Tang H, Sun Y, Shi Z, et al. YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-κB pathways, causing bronchial smooth muscle proliferation and migration. J Immunol 2013; 190:438-446.
39. Du R, Litonjua AA, Tantisira KG, et al. Genome-wide association study reveals class I MHC-restricted T cell-associated molecule gene (CRTAM) variants interact with vitamin D levels to affect asthma exacerbations. J Allergy Clin Immunol 2012; 129:368-373.
40. Xu M, Tantisira KG, Wu A, et al. Genome Wide Association Study to predict severe asthma exacerbations in children using random forests classifiers. BMC Med Genet 2011; 12:90.
41. Tavendale R, Macgregor DF, Mukhopadhyay S, Palmer CN. A polymorphism controlling ORMDL3 expression is associated with asthma that is poorly controlled by current medications. J Allergy Clin Immunol 2008; 121:860-863. (Pubitemid 351471721)
42. 2 adrenoceptor polymorphism. Thorax 2000; 55:762-767. (Pubitemid 30660904)
43. 2- receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol 2009; 124:1188-1194.
44. Holloway JW, Dunbar PR, Riley GA, et al. Association of β2-adrenergic receptor polymorphisms with severe asthma. Clin Exp Allergy 2000; 30:1097-1103. (Pubitemid 30619762)
45. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370:2118-2125. (Pubitemid 350296302)
46. Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of β2-adrenergic receptor polymorphism on response to longacting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009; 374:1754-1764.
47. Bleecker ER, Nelson HS, Kraft M, et al. β2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010; 181:676-687.
48. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100:3184-3188. (Pubitemid 28022857)
49. Dewar JC, Wilkinson J, Wheatley A, et al. The glutamine 27 b2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol 1997; 100:261-265. (Pubitemid 27349870)
50. 2-adrenergic receptor polymorphisms in the childhood asthma management program. J Allergy Clin Immunol 2003; 112:870-876. (Pubitemid 37412053)
51. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75-80. (Pubitemid 30469801)
52. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505-1512. (Pubitemid 39410416)
53. Sohn MH, Lee JH, Kim KW, et al. Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy. Am J Respir Crit Care Med 2009; 179:449-456.
54. Tang H, Fang Z, Sun Y, et al. YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E. Eur Respir J 2010; 35:757-760.
55. Ortega H, Prazma C, Suruki RY, et al. Association of CHI3L1 in African-Americans with prior history of asthma exacerbations and stress. J Asthma 2013; 50:7-13.
56. Koster ES, Maitland-van der Zee AH, Tavendale R, et al. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. Allergy 2011; 66:1546-1552.
57. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway poly-morphisms on response to montelukast in asthma. AmJ Respir Crit Care Med 2006; 173:379-385. (Pubitemid 43228324)
58. Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygen-ase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007; 17:189-196. (Pubitemid 46668003)
59. Holloway JW, Barton SJ, Holgate ST, et al. The role of LTA4H and ALOX5AP polymorphism in asthma and allergy susceptibility. Allergy 2008; 63:1046-1053.
60. Bisgaard H, Bonnelykke K, Sleiman PM, et al. Chromosome 17q21 gene variants are associated with asthma and exacerbations but not atopy in early childhood. Am J Respir Crit Care Med 2009; 179:179-185.
61. Moffatt MF, Kabesch M, Liang L, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007; 448: 470-473. (Pubitemid 47123521)
62. Halapi E, Gudbjartsson DF, Jonsdottir GM, et al. A sequence variant on 17q21 is associated with age at onset and severity of asthma. Eur J Hum Genet 2010; 18:902-908.
63. Kang MJ, Yu HS, Seo JH, et al. GSDMB/ORMDL3 variants contribute to asthma susceptibility and eosinophil-mediated bronchial hyperresponsive-ness. Hum Immunol 2012; 73:954-959.
64. Wenzel SE, Balzar S, Ampleford E, et al. IL4R a mutations are associated with asthma exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med 2007; 175:570-576. (Pubitemid 46438941)
65. Slager RE, Otulana BA, Hawkins GA, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol 2012; 130:516-522.
66. Hershey GK, Friedrich MF, Esswein LA, et al. The association of atopy with a gain-of-function mutation in the a subunit of the interleukin-4 receptor. N Engl J Med 1997; 337:1720-1725. (Pubitemid 27527768)
67. Rosa-Rosa L, Zimmermann N, Bernstein JA, et al. The R576 IL-4 receptor a allele correlates with asthma severity. J Allergy Clin Immunol 1999; 104:1008-1014. (Pubitemid 29532122)
68. Howard TD, Koppelman GH, Xu J, et al. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet 2002; 70:230-236. (Pubitemid 34031711)
69. 7-Regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy. Am J Respir Crit Care Med 2013; 187:28-33.
70. Bateman ED, Reddel HK, Eriksson G, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010; 125:600-608.
71. O'Connor RD, Bleecker ER, Long A, et al. Subacute lack of asthma control and acute asthma exacerbation history as predictors of subsequent acute asthma exacerbations: evidence from managed care data. J Asthma 2010; 47:422-428.
72. Stephenson JJ, Quimbo RA, Gutierrez B. Subacute lack of asthma control as a predictor of subsequent acute asthma exacerbation in a managed care population. Am J Manag Care 2010; 16:108-114.
73. Meltzer EO, Busse WW, Wenzel SE, et al. Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol 2011; 127:167-172.
74. Wei HH, Zhou T, Wang L, et al. Current asthma control predicts future risk of asthma exacerbation: a 12-month prospective cohort study. Chin Med J (Engl) 2012; 125:2986-2993.
75. Miller MK, Lee JH, Miller DP, Wenzel SE. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 2007; 101:481-489. (Pubitemid 46196331)
76. Covar RA, Szefler SJ, Zeiger RS, et al. Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children. J Allergy Clin Immunol 2008; 122:741-747.
77. Haselkorn T, Fish JE, Chipps BE, et al. Effect of weight change on asthma-related health outcomes in patients with severe or difficult-to-treat asthma. Respir Med 2009; 103:274-283.
78. Chipps BE, Zeiger RS, Borish L, et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 2012; 130:332-342.
79. Thomson NC, Chaudhuri R. Identification and management of adults with asthma prone to exacerbations: can we do better? BMC Pulm Med 2008; 8:27.
80. Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy 2009; 39:193-202.
81. Thurston GD, LippmannM, Scott MB, Fine JM. Summertime haze air pollution and children with asthma. Am J Respir Crit Care Med 1997; 155:654-660. (Pubitemid 27085816)
82. Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy 2011; 66:818-829.
83. Lewis SA, Corden JM, Forster GE, Newlands M. Combined effects of aerobiological pollutants, chemical pollutants and meteorological conditions on asthma admissions and A & E attendances in Derbyshire UK, 1993-96. Clin Exp Allergy 2000; 30:1724-1732. (Pubitemid 32011751)
84. Galan I, Prieto A, Rubio M, et al. Association between airborne pollen and epidemic asthma in Madrid, Spain: a case-control study. Thorax 2010; 65:398-402.
85. Pulimood TB, Corden JM, Bryden C, et al. Epidemic asthma and the role of the fungal mold Alternaria alternata. J Allergy Clin Immunol 2007; 120:610-617. (Pubitemid 47320756)
86. Johnston NW, Johnston SL, Duncan JM, et al. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol 2005; 115:132-138. (Pubitemid 40075433)
87. Johnston NW, Johnston SL, Norman GR, et al. The September epidemic of asthma hospitalization: school children as disease vectors. J Allergy Clin Immunol 2006; 117:557-562. (Pubitemid 43340218)
88. Busse WW, Lemanske RF Jr, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet 2010; 376:826-834.
89. 2LEN-DARE systematic review. Allergy 2011; 66:458-468.
90. Dulek DE, Peebles RS Jr. Viruses and asthma. Biochim Biophys Acta 2011; 1810:1080-1090.
91. Khetsuriani N, Kazerouni NN, Erdman DD, et al. Prevalence of viral respiratory tract infections in children with asthma. J Allergy Clin Immunol 2007; 119:314-321. (Pubitemid 46204808)
92. Corne JM, Marshall C, Smith S, et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and nonasthmatic individuals: a longitudinal cohort study. Lancet 2002; 359:831-834. (Pubitemid 34233753)
93. Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006; 12:1023-1026. (Pubitemid 44353382)
94. Olenec JP, Kim WK, Lee WM, et al. Weekly monitoring of children with asthma for infections and illness during common cold seasons. J Allergy Clin Immunol 2010; 125:1001-1006.
95. Green RM, Custovic A, Sanderson G, et al. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ 2002; 324:763.
96. Murray CS, Poletti G, Kebadze T, et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax 2006; 61:376-382. (Pubitemid 43723318)
97. Denlinger LC, Sorkness RL, Lee WM, et al. Lower airway rhinovirus burden and the seasonal risk of asthma exacerbation. Am J Respir Crit Care Med 2011; 184:1007-1014.
98. Mak RK, Tse LY, Lam WY, et al. Clinical spectrum of human rhinovirus infections in hospitalized Hong Kong children. Pediatr Infect Dis J 2011; 30:749-753.
99. Bizzintino J, Lee WM, Laing IA, et al. Association between human rhinovirus C and severity of acute asthma in children. Eur Respir J 2011; 37:1037-1042.
100. Gern JE, Galagan DM, Jarjour NN, et al. Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. Am J Respir Crit Care Med 1997; 155:1159-1161. (Pubitemid 27133440)
101. Wos M, Sanak M, Soja J, et al. The presence of rhinovirus in lower airways of patients with bronchial asthma. Am J Respir Crit Care Med 2008; 177:1082-1089. (Pubitemid 351717566)
102. Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005; 201:937-947. (Pubitemid 40524463)
103. Message SD, Laza-Stanca V, Mallia P, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A 2008; 105:13562-13567.
104. Baraldo S, Contoli M, Bazzan E, et al. Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma. J Allergy Clin Immunol 2012; 130:1307-1314.
105. Sykes A, Edwards MR, Macintyre J, et al. Rhinovirus 16-induced IFN - a and IFN-b are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol 2012; 129:1506-1514.
106. Durrani SR, Montville DJ, Pratt AS, et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol 2012; 130:489-495.
107. Laza-Stanca V, Message SD, Edwards MR, et al. The role of IL-15 deficiency in the pathogenesis of virus-induced asthma exacerbations. PLoS Pathog 2011; 7:e1002114.
108. Subrata LS, Bizzintino J, Mamessier E, et al. Interactions between innate antiviral and atopic immunoinflammatory pathways precipitate and sustain asthma exacerbations in children. J Immunol 2009; 183:2793-2800.
109. Santiago J, Hernandez-Cruz JL, Manjarrez-Zavala ME, et al. Role of monocyte chemotactic protein-3 and -4 in children with virus exacerbation of asthma. Eur Respir J 2008; 32:1243-1249.
110. Chan CK, Kuo ML, Yeh KW, et al. Sequential evaluation of serum monocyte chemotactic protein 1 among asymptomatic state and acute exacerbation and remission of asthma in children. J Asthma 2009; 46:225-228.
111. Kato M, Yamada Y, Maruyama K, Hayashi Y. Serum eosinophil cationic protein and 27 cytokines/chemokines in acute exacerbation of childhood asthma. Int Arch Allergy Immunol 2010; 152 (Suppl 1):62-66.
112. Kato A, Favoreto S Jr, Avila PC, Schleimer RP. TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. J Immunol 2007; 179:1080-1087.
113. Torres D, Dieudonne A, Ryffel B, et al. Double-stranded RNA exacerbates pulmonary allergic reaction through TLR3: implication of airway epithelium and dendritic cells. J Immunol 2010; 185:451-459.
114. Uller L, Leino M, Bedke N, et al. Double-stranded RNA induces disproportionate expression of thymic stromal lymphopoietin versus interferon-b in bronchial epithelial cells from donors with asthma. Thorax 2010; 65:626-632.
115. Nagarkar DR, Poposki JA, Comeau MR, et al. Airway epithelial cells activate TH2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin. J Allergy Clin Immunol 2012; 130:225-232.
116. Ulrik CS. Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma. Clin Exp Allergy 1995; 25:820-827.
117. Pizzichini MM, Pizzichini E, Clelland L, et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur Respir J 1999; 13:15-21. (Pubitemid 29079213)
118. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161:64-72. (Pubitemid 30055904)
119. Lonnkvist K, Hellman C, Lundahl J, et al. Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal. J Allergy Clin Immunol 2001; 107:812-817. (Pubitemid 32436914)
120. Deykin A, Lazarus SC, Fahy JV, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005; 115:720-727. (Pubitemid 40460845)
121. Belda J, Parameswaran K, Lemiere C, et al. Predictors of loss of asthma control induced by corticosteroid withdrawal. Can Respir J 2006; 13:129-133. (Pubitemid 43834003)
122. Li AM, Tsang TW, Lam HS, et al. Predictors for failed dose reduction of inhaled corticosteroids in childhood asthma. Respirology 2008; 13:400-407. (Pubitemid 351503131)
123. Velthove KJ, Bracke M, Souverein PC, et al. Identification of exacerbations in obstructive lung disease through biomarkers. Biomarkers 2009; 14:523-528.
124. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-993.
125. Gagliardo R, La Grutta S, Chanez P, et al. Noninvasive markers of airway inflammation and remodeling in childhood asthma. Pediatr Allergy Immunol 2009; 20:780-790.
126. Coleman JM, Naik C, Holguin F, et al. Epithelial eotaxin-2 and eotaxin-3 expression: relation to asthma severity, luminal eosinophilia and age at onset. Thorax 2012; 67:1061-1066.
127. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-984.
128. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651-659.
129. Wu AC, Tantisira K, Li L, et al. Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. Chest 2011; 140:100-107.
130. Wu W, Chen Y, d'Avignon A, Hazen SL. 3-Bromotyrosine and 3,5-dibro-motyrosine are major products of protein oxidation by eosinophil peroxidase: potential markers for eosinophil-dependent tissue injury in vivo. Biochemistry (Mosc) 1999; 38:3538-3548.
131. Wedes SH, Wu W, Comhair SA, et al. Urinary bromotyrosine measures asthma control and predicts asthma exacerbations in children. J Pediatr 2011; 159:248-255.
132. Wedes SH, Khatri SB, Zhang R, et al. Noninvasive markers of airway inflammation in asthma. Clin Transl Sci 2009; 2:112-117.
133. Nielsen LP, Bjerke T, Christensen MB, et al. Eosinophil markers in seasonal allergic rhinitis: intranasal fluticasone propionate inhibits local and systemic increases during the pollen season. Allergy 1998; 53:778-785. (Pubitemid 28374759)
134. Kurt E, Bavbek S, Aksu O, et al. The effect of natural pollen exposure on eosinophil apoptosis and its relationship to bronchial hyperresponsiveness in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005; 95:72-78. (Pubitemid 41022776)
135. Acland JD, Gould AH. Normal variation in the count of circulating eosinophils in man. J Physiol 1956; 133:456-466.
136. Spector SL, Tan RA. Is a single blood eosinophil count a reliable marker for 'eosinophilic asthma?'. J Asthma 2012; 49:807-810.
137. Ohrui T, Funayama T, Sekizawa K, et al. Effects of inhaled beclomethasone dipropionate on serum IgE levels and clinical symptoms in atopic asthma. Clin Exp Allergy 1999; 29:357-361. (Pubitemid 29145136)
138. ten Brinke A, Zwinderman AH, Sterk PJ, et al. Refractory' eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170:601-605. (Pubitemid 39202200)
139. 4 levels identify children with tobacco smoke exposure at risk for asthma exacerbation. J Allergy Clin Immunol 2011; 128:323-327.
140. Robroeks CM, van Vliet D, Jobsis Q, et al. Prediction of asthma exacerbations in children: results of a one-year prospective study. Clin Exp Allergy 2012; 42:792-798.
141. Harkins MS, Fiato KL, Iwamoto GK. Exhaled nitric oxide predicts asthma exacerbation. J Asthma 2004; 41:471-476. (Pubitemid 38955405)
142. Pijnenburg MW, Bakker EM, Lever S, et al. High fractional concentration of nitric oxide in exhaled air despite steroid treatment in asthmatic children. Clin Exp Allergy 2005; 35:920-925. (Pubitemid 41032541)
143. Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163:406-412. (Pubitemid 32158520)
144. Cabral AL, Vollmer WM, Barbirotto RM, Martins MA. Exhaled nitric oxide as a predictor of exacerbation in children with moderate-to-severe asthma: a prospective, 5-month study. Ann Allergy Asthma Immunol 2009; 103: 206-211.
145. Ko FW, Hui DS, Leung TF, et al. Evaluation of the asthma control test: a reliable determinant of disease stability and a predictor of future exacerbations. Respirology 2012; 17:370-378.
146. Brehm JM, Schuemann B, Fuhlbrigge AL, et al. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. J Allergy Clin Immunol 2010; 126:52-58.
147. Brehm JM, Acosta-Perez E, Klei L, et al. Vitamin D insufficiency and severe asthma exacerbations in Puerto Rican children. Am J Respir Crit Care Med 2012; 186:140-146.
148. Majak P, Olszowiec-Chlebna M, Smejda K, Stelmach I. Vitamin D supple-mentation in children may prevent asthma exacerbation triggered by acute respiratory infection. J Allergy Clin Immunol 2011; 127:1294-1296.
149. Wiley JS, Sluyter R, Gu BJ, et al. The human P2X7 receptor and its role in innate immunity. Tissue Antigens 2011; 78:321-332.
150. Denlinger LC, Shi L, Guadarrama A, et al. Attenuated P2X7 pore function as a risk factor for virus-induced loss of asthma control. Am J Respir Crit Care Med 2009; 179:265-270.
151. 7 function. J Allergy Clin Immunol 2012; 130:496-502.
152. Fuhlbrigge AL, Weiss ST, Kuntz KM, Paltiel AD. Forced expiratory volume in 1 s percentage improves the classification of severity among children with asthma. Pediatrics 2006; 118:e347-e355. (Pubitemid 46085375)
153. Wu AC, Gregory M, Kymes S, et al. Modeling asthma exacerbations through lung function in children. J Allergy Clin Immunol 2012; 130:1065-1070.
154. Rao DR, Gaffin JM, Baxi SN, et al. The utility of forced expiratory flow between 25% and 75% of vital capacity in predicting childhood asthma morbidity and severity. J Asthma 2012; 49:586-592.
155. Shi Y, Aledia AS, Galant SP, George SC. Peripheral airway impairment measured by oscillometry predicts loss of asthma control in children. J Allergy Clin Immunol 2012. In press.
156. Shaw D, Green R, Berry M, et al. A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma. Prim Care Respir J 2012; 21:283-287.
157. Dennis SM, Altmann DR, Lee TH. Increase in daytime symptoms isasensitive and specific criterion for predicting corticosteroid-treated exacerbations in a clinical asthma trial. Clin Exp Allergy 2005; 35:308-312. (Pubitemid 40516656)
158. Frey U, Brodbeck T, Majumdar A, et al. Risk of severe asthma episodes predicted from fluctuation analysis of airway function. Nature 2005; 438: 667-670. (Pubitemid 41740576)
159. Thamrin C, Zindel J, Nydegger R, et al. Predicting future risk of asthma exacerbations using individual conditional probabilities. J Allergy Clin Immunol 2011; 127:1494-1502.
160. Gonem S, Umar I, Burke D, et al. Airway impedance entropy and exacerbations in severe asthma. Eur Respir J 2012; 40:1156-1163.
161. Shireman TI, Heaton PC, Gay WE, et al. Relationship between asthma drug therapy patterns and healthcare utilization. Ann Pharmacother 2002; 36:557-564. (Pubitemid 34270265)
162. Schatz M, Zeiger RS, Vollmer WM, et al. Validation of a b-agonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol 2006; 117:995-1000.
163. Zeiger RS, Yegin A, Simons FE, et al. Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations. Ann Allergy Asthma Immunol 2012; 108:81-87.
164. Nestor A, Calhoun AC, Dickson M, Kalik CA. Cross-sectional analysis of the relationship between national guideline recommended asthma drug therapy and emergency/hospital use within a managed care population. Ann Allergy Asthma Immunol 1998; 81:327-330. (Pubitemid 28498997)
165. Swern AS, Tozzi CA, Knorr B, Bisgaard H. Predictinganasthma exacerbation in children 2 to5 years of age. Ann Allergy Asthma Immunol 2008; 101:626-630.
166. Lieu TA, Quesenberry CP, Sorel ME, et al. Computer-based models to identify high-risk children with asthma. Am J Respir Crit Care Med 1998; 157:1173-1180.
167. Li D, German D, Lulla S, et al. Prospective study of hospitalization for asthma. A preliminary risk factor model. Am J Respir Crit Care Med 1995; 151:647-655.
168. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59-65. (Pubitemid 38096162)
169. Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006; 117:549-556. (Pubitemid 43340217)
170. Schatz M, Kosinski M, Yarlas AS, et al. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 2009; 124:719-723.
171. Haselkorn T, Fish JE, Zeiger RS, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 2009; 124:895-902.
172. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14:902-907. (Pubitemid 29519356)
173. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99:553-558. (Pubitemid 40468501)
174. Greenberg S, Liu N, Kaur A, et al. The asthma disease activity score: a discriminating, responsive measure predicts future asthma attacks. J Allergy Clin Immunol 2012; 130:1071-1077.
175. Schatz M, Mosen D, Kosinski M, et al. Validation of the asthma impact survey, a brief asthma-specific quality of life tool. Qual Life Res 2007; 16:345-355. (Pubitemid 46088366)
176. Schatz M, Zeiger RS, Yang SJ, et al. Further validation and definition of the psychometric properties of the Asthma Impact Survey. J Allergy Clin Immunol 2011; 128:44-49.
177. Schatz M, Zeiger RS, Yang SJ, et al. The relationship of asthma impairment determined by psychometric tools to future asthma exacerbations. Chest 2012; 141:66-72.
178. Forno E, Fuhlbrigge A, Soto-Quiros ME, et al. Risk factors and predictive clinical scores forasthma exacerbationsinchildhood. Chest 2010; 138:1156-1165.
179. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 1998; 114:998-1007. (Pubitemid 28495893)
180. Bime C, Wei CY, Holbrook JT, et al. Asthma symptom utility index: reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. J Allergy Clin Immunol 2012; 130:1078-1084.
181. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47:81-87. (Pubitemid 24034293)
182. Tierney WM, Roesner JF, Seshadri R, et al. Assessing symptoms and peak expiratory flow rate as predictors of asthma exacerbations. J Gen Intern Med 2004; 19:237-242. (Pubitemid 38388933)
183. Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999; 14:32-38. (Pubitemid 29411232)